TMO
Thermo Fisher Scientific Inc.570.16
-5.75-1%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
FY Q3 '25
Reshoring tailwinds, clinical acceleration
Q&A spotlighted pharma customers' confidence navigating tariffs through U.S. reshoring, driving near-term demand for bioprocessing equipment and Patheon fill-finish capacity while startup activity adds incremental tailwinds. Clinical research accelerated to low-single-digit growth with strong authorizations and accelerator program wins, especially in biotech. Management reaffirmed 3-6% organic trajectory into 2026, unpacking Solventum ($750M revenue, $0.06 dilutive) and Sanofi ($0.05 dilutive) details. Academic/government muted by shutdown hesitancy, baked into Q4 guide; China declines mid-high single digits. Bioproduction bookings outpace strong teens growth. Investors eye reshoring ramp.
Key Stats
Market Cap
214.21BP/E (TTM)
32.90Basic EPS (TTM)
17.33Dividend Yield
0%Recent Filings
8-K
€2.1B euro notes issued
Thermo Fisher International issued €1B floating rate senior notes due 2027 and €1.1B 3.628% fixed rate senior notes due 2035 on December 1, 2025, fully guaranteed by the parent company. Net proceeds of ~€2.09B target general corporate purposes like acquisitions or debt refinancing. Covenants limit liens on key assets. Change of control triggers repurchase offers.
10-Q
Q3 FY2025 results
Thermo Fisher Scientific posted solid Q3 results, with revenues climbing 5% year-over-year to $11.1B, fueled by 3% organic growth (derived) from robust bioproduction demand in pharma and biotech, while academic spending cooled amid uncertainty. Operating income edged up 6% to $1.9B, lifting the margin to 17.4%, thanks to productivity gains that offset restructuring costs and acquisition impacts; diluted EPS held steady at $4.27. Acquisitions like the $3.9B Solventum filtration business bolstered Life Sciences Solutions, adding $2.1B in goodwill, and a pending $8.9B Clario deal eyes clinical trial expansion by mid-2026. Cash dipped to $2.0B with $3.3B FCF (derived) supporting $3.0B in buybacks, while total debt rose to $35.7B under a $5B revolver with no draws. Yet regulatory hurdles could snag that Clario close.
8-K
Acquires Clario for $8.9B
Thermo Fisher signed a definitive agreement on October 29, 2025, to buy Clario for $8.875 billion cash at close, plus $125 million deferred and up to $400 million contingent. Expected to close mid-2026 pending approvals, it adds Clario's $1.25 billion 2025 revenue and endpoint data platform to bolster clinical trial insights. Accretive to adjusted EPS immediately post-close. Regulatory hurdles loom.
8-K
Q3 revenue up 5%, EPS gains 10%
Thermo Fisher Scientific reported third-quarter 2025 revenue of $11.12 billion, up 5% from last year, with organic growth at 3%. Adjusted EPS climbed 10% to $5.79, fueled by operational excellence and new product launches like the Oncomine Dx Express Test. Acquisitions of Solventum's Filtration and Separation business and Sanofi's Ridgefield site bolstered bioproduction capacity, while a $1.0 billion stock repurchase underscored confidence. Updated 2025 guidance awaits the earnings call.
8-K
Thermo Fisher issues $2.5B notes
Thermo Fisher Scientific issued $2.5 billion in senior notes on October 7, 2025, comprising $500 million 4.200% due 2031, $750 million 4.473% due 2032, $750 million 4.794% due 2035, and $500 million 4.894% due 2037. Net proceeds of approximately $2.48 billion will fund general corporate purposes, including potential acquisitions, debt repayment, and capital expenditures. The notes carry standard redemption options and covenants limiting secured debt. Investors gain from flexible capital access amid market conditions.
IPO
Website
Employees
Sector
Industry
A
Agilent Technologies, Inc.
139.19-1.41
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BRKR
Bruker Corporation
44.96-0.71
DGX
Quest Diagnostics Incorporated
178.66-5.45
DHR
Danaher Corporation
224.70-3.83
ILMN
Illumina, Inc.
131.56-3.36
QGEN
Qiagen N.V.
45.01-0.43
RVTY
Revvity, Inc.
96.27-2.81
TWST
Twist Bioscience Corporation
31.13+0.06
WAT
Waters Corporation
378.53-6.89